Unveiling the structural spectrum of SARS-CoV-2 fusion by in situ cryo-ET., PMID:40461447
Ultrapotent SARS coronavirus-neutralizing single-domain antibodies that clamp the spike at its base., PMID:40447603
Characterization of Nanobody Binding to Distinct Regions of the SARS-CoV-2 Spike Protein by Flow Virometry., PMID:40285013
Self-assembled epitope-based nanoparticles targeting the SARS-CoV-2 spike protein enhanced the immune response and induced potential broad neutralizing activity., PMID:40270771
Anti-S2 antibodies responsible for the SARS-CoV-2 infection-induced serological cross-reactivity against MERS-CoV and MERS-related coronaviruses., PMID:40226608
Structural basis and mode of action for two broadly neutralizing nanobodies targeting the highly conserved spike stem-helix of sarbecoviruses including SARS-CoV-2 and its variants., PMID:40215243
Capture of fusion-intermediate conformations of SARS-CoV-2 spike requires receptor binding and cleavage at either the S1/S2 or S2' site., PMID:40198676
RBD-depleted SARS-CoV-2 spike generates protective immunity in cynomolgus macaques., PMID:40159504
Membrane-targeted immunogenic compositions using exosome mimetic approach for vaccine development against SARS-CoV-2 and other pathogens., PMID:40157987
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma., PMID:40133428
Targeting the early life stages of SARS-CoV-2 using a multi-peptide conjugate vaccine., PMID:40088511
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants., PMID:40000611
NIEAs elicited by wild-type SARS-CoV-2 primary infection fail to enhance the infectivity of Omicron variants., PMID:39994733
Epitope-focused vaccine immunogens design using tailored horseshoe-shaped scaffold., PMID:39966941
A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses., PMID:39955548
A novel method for detecting SARS-CoV-2 IgM and IgG based on the gold immune chromatography assay., PMID:39929938
Structural prediction of chimeric immunogen candidates to elicit targeted antibodies against betacoronaviruses., PMID:39908344
Passive infusion of an S2-Stem broadly neutralizing antibody protects against SARS-CoV-2 infection and lower airway inflammation in rhesus macaques., PMID:39847599
Reverse mutational scanning of SARS-CoV-2 spike BA.2.86 identifies epitopes contributing to immune escape from polyclonal sera., PMID:39827186
Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice., PMID:39774966
Characterization of Site-Specific N- and O-Glycopeptides from Recombinant Spike and ACE2 Glycoproteins Using LC-MS/MS Analysis., PMID:39769415
Structural Immunology of SARS-CoV-2., PMID:39731211
Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults., PMID:39723823
SARS-CoV-2 Omicron variations reveal mechanisms controlling cell entry dynamics and antibody neutralization., PMID:39621785
Discovery of anti-SARS-CoV-2 S2 protein antibody CV804 with broad-spectrum reactivity with various beta coronaviruses and analysis of its pharmacological properties in vitro and in vivo., PMID:39621673
Structural characterization of human monoclonal antibodies targeting uncommon antigenic sites on spike glycoprotein of SARS-CoV., PMID:39589795
A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection., PMID:39548371
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection., PMID:39516286
Antibody Responses in SARS-CoV-2-Exposed and/or Vaccinated Individuals Target Conserved Epitopes from Multiple CoV-2 Antigens., PMID:39337303
Discovery and characterization of a pan-betacoronavirus S2-binding antibody., PMID:39326419
Sequence Matters: Primary COVID-19 Vaccination after Infection Elicits Similar Anti-spike Antibody Levels, but Stronger Antibody Dependent Cell-mediated Cytotoxicity than Breakthrough Infection., PMID:39248629
A nonadjuvanted HLA-restricted peptide vaccine induced both T and B cell immunity against SARS-CoV-2 spike protein., PMID:39242614
Characterization of monoclonal antibodies targeting SARS-CoV-2 spike glycoprotein: Reactivity against Delta and Omicron BA.1 variants., PMID:39216601
Simulation-driven design of stabilized SARS-CoV-2 spike S2 immunogens., PMID:39191724
Diversified humoral immunity and impacts of booster vaccines: SARS-CoV-2 antibody profile and Omicron BA.2 neutralization before and after first or second boosters., PMID:39162540
Structure and inhibition of SARS-CoV-2 spike refolding in membranes., PMID:39146425
Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein., PMID:39125749
Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients., PMID:39122634
Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination., PMID:39094579
Evidence that the SARS-CoV-2 S protein undergoes a conformational change at the Golgi complex that leads to the formation of virus neutralising antibody binding epitopes in the S1 protein subunit., PMID:39094503
The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2., PMID:39093891
SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition., PMID:39059371
Heterologous booster vaccination enhances antibody responses to SARS-CoV-2 by improving Tfh function and increasing B-cell clonotype SHM frequency., PMID:38975334
A broadly generalizable stabilization strategy for sarbecovirus fusion machinery vaccines., PMID:38944664
Evidences support that dengue virus can impart broad-spectrum immunity against betacoronaviruses in dengue endemic regions., PMID:38932494
Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection., PMID:38830902
Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells., PMID:38807606
Humoral anti-SARS-CoV-2 response in patients with different long COVID phenotypes., PMID:38805803
The Effect of Age and Comorbidities: Children vs. Adults in Their Response to SARS-CoV-2 Infection., PMID:38793682
Role of prior immunity in binding to spike of "future" Omicron subvariants., PMID:38782260
For research use only. Not for human or drug use.
